Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR5A1 | Q13285 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | LTA4H | P09960 | 4/20 | 0.56 |
| ▸ | PLA2G4B | P0C869 | 5/20 | 0.56 |
| ▸ | RARB | P10826 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29658410 | 1.00 | NR5A1 (0.65) | NR5A1TP53TSHRLTA4HPLA2G4B | |
| SCHEMBL29261748 | 0.98 | NR5A1 (0.61) | NR5A1TP53TSHRLTA4HPLA2G4B | |
| SCHEMBL2772370 | 0.94 | LTA4H (0.55) | NR5A1TP53TSHRLTA4HPLA2G4B | |
| SCHEMBL7929638 | 0.92 | NR5A1 (0.56) | NR5A1TP53TSHRLTA4HPLA2G4B | |
| SCHEMBL7928208 | 0.90 | NR5A1 (0.53) | NR5A1TP53TSHRLTA4HPLA2G4B | |
| SCHEMBL6397166 | 0.89 | NR5A1 (0.65) | NR5A1TP53TSHRLTA4HPLA2G4B | |
| SCHEMBL2413751 | 0.86 | LTA4H (0.55) | NR5A1TSHRLTA4HNPC1LMNA | |
| SCHEMBL3157088 | 0.86 | RARB (0.55) | NR5A1TP53TSHRLTA4HRARB | |
| SCHEMBL6398893 | 0.85 | NR5A1 (0.63) | NR5A1TP53TSHRLTA4HPLA2G4B | |
| SCHEMBL8936597 | 0.84 | NR5A1 (0.79) | NR5A1TP53TSHRLTA4HPLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114478500-A | Coumarin two-photon initiator and synthesis method and application thereof | 浙江大学 | 2022-05-13 | — | — | CN | claimed |
| EP-0735880-A1 | USE OF VANADIUM MOLYBDENUM OR TUNGSTEN COMPLEXES FOR CONTROLLING CELLULAR PROLIFERATION | Bristol-Myers Squibb Company (US) | 1996-10-09 | — | — | EP | claimed |
| WO-1995020390-A1 | USE OF VANADIUM MOLYBDENUM OR TUNGSTEN COMPLEXES FOR CONTROLLING CELLULAR PROLIFERATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-08-03 | — | — | WO | claimed |
| US-20240316055-A1 | METHODS FOR TREATING LEIGH SYNDROME | DBCC RES LLC (US) | 2024-09-26 | — | — | US | disclosed |
| US-20230242681-A1 | POLYMERIZATION INITIATOR, KIT FOR PREPARING CURABLE COMPOSITION, CURABLE COMPOSITION, CURED PRODUCT, AND DENTAL MATERIAL | MITSUI CHEMICALS, INC. (JP) | 2023-08-03 | — | — | US | disclosed |
| EP-4166578-A1 | POLYMERIZATION INITIATOR, KIT FOR PREPARING CURABLE COMPOSITION, CURABLE COMPOSITION, CURED PRODUCT, AND DENTAL MATERIAL | Mitsui Chemicals, Inc. (JP) | 2023-04-19 | — | — | EP | disclosed |
| EP-1454921-B1 | RADICAL POLYMERIZATION CATALYSTS AND ADHESIVE KIT FOR DENTAL USE | TOKUYAMA CORP (JP) | 2021-07-28 | — | — | EP | disclosed |
| US-20050009946-A1 | Radical polymerization catalyst and adhesive kit for dental use | TOKUYAMA CORPORATION (JP) | 2005-01-13 | — | — | US | disclosed |
| EP-1454921-A1 | RADICAL POLYMERIZATION CATALYSTS AND ADHESIVE KIT FOR DENTAL USE | Tokuyama Corporation (JP) | 2004-09-08 | — | — | EP | disclosed |
| US-5877210-A | CONTROLLING IMMUNE RESPONSE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-03-02 | — | — | US | disclosed |
| US-5846998-A | Use of phosphotyrosine phosphatase inhibitors or phosphotyrosine kinase activators for controlling cellular proliferation | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-12-08 | — | — | US | disclosed |
| EP-0735880-A1 | USE OF VANADIUM MOLYBDENUM OR TUNGSTEN COMPLEXES FOR CONTROLLING CELLULAR PROLIFERATION | Bristol-Myers Squibb Company (US) | 1996-10-09 | — | — | EP | disclosed |
| WO-1995020390-A1 | USE OF VANADIUM MOLYBDENUM OR TUNGSTEN COMPLEXES FOR CONTROLLING CELLULAR PROLIFERATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240316055-A1 | METHODS FOR TREATING LEIGH SYNDROME | ECHS1, GLS2, OAT | NR5A1 3388/4885TP53 4714/4885TSHR 4168/4885 |
| US-20230242681-A1 | POLYMERIZATION INITIATOR, KIT FOR PREPARING CURABLE COMPOSITION, CURABLE COMPOSITION, CURED PRODUCT, AND DENTAL MATERIAL | KIT, SETDB1, NOD1 | NR5A1 3380/4885TP53 3489/4885TSHR 4406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.